Compare Inovio Pharmaceuticals Inc (INO) vs United Microelectronics Corp (UMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs United Microelectronics Corp — how do they compare? Inovio Pharmaceuticals Inc trades at $1.15 (market cap $112.19M), while United Microelectronics Corp trades at $22.96 (market cap $58.02B). The key difference: United Microelectronics Corp is far larger — about 517.2× Inovio Pharmaceuticals Inc's market cap, and United Microelectronics Corp pays a 1.76% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and United Microelectronics Corp for 42 Days on average.
| INO | UMC | |
|---|---|---|
Market Cap | $112.19M | $58.02B |
Volume | 3,201,278 | 11,897,809 |
Sector | Health | Technology |
52-Week High | $2.65 | $28.02 |
52-Week Low | $0.66 | $7.02 |
Typical Hold Time | 43 Days | 42 Days |
Enterprise Value | $83.51M | $55.10B |
Dividend Yield | — | 1.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO Pharmaceuticals trades at $1.09, down 5.63% today, with a bearish technical outlook despite positive analyst sentiment. The company faces significant fundamental challenges with minimal revenue of $65,340 in 2025 and substantial losses of $84.95 million. Key catalyst is the October 30, 2026 FDA decision on INO-3107 for recurrent respiratory papillomatosis, which could transform the company's prospects if approved.
Investment outlook hinges on FDA approval of INO-3107, with analysts maintaining a $2.75 consensus target representing 152% upside. However, persistent cash burn and negative profitability metrics pose substantial risks. The stock offers high-risk, high-reward potential for investors comfortable with binary regulatory outcomes in biotech.
UMC trades at $22.82, down 2.1% over the past day, with a bullish technical signal but bearish moving averages. The company reported strong recent earnings beats, with Q2 2026 EPS of $0.54 versus $0.16 expected. Revenue for 2025 was $237.55B, with a net income margin of 16.99%. Analyst consensus is mixed, with 26.67% buy ratings and 53.33% hold. Recent news highlights AI-driven growth opportunities and a DCF intrinsic value estimate of $29.
The outlook for UMC is cautiously optimistic, driven by strong earnings performance and expanding AI opportunities. Key risks include competitive pressures in the semiconductor foundry space and potential volatility from AI spending fluctuations. The stock's current valuation metrics, including a P/E of 22.03, suggest room for growth if earnings trends continue.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About United Microelectronics Corp
Founded in 1980, United Microelectronics is the world's third-largest dedicated chip foundry, with 7% market share in 2021, according to Gartner, after TSMC and GlobalFoundries. UMC's headquarters are in Hsinchu, Taiwan, and it operates 12 fabs in Taiwan, Mainland China, Japan and Singapore, with additional sales offices in Europe, the U.S. and South Korea. UMC features a diverse customer base including Texas Instruments, MediaTek, Qualcomm, Broadcom, Xilinx and Realtek, supplying a wide range of products applied in communications, display, memory, automotive and more. UMC employs about 20,000 people.
Read more on UMC →
